Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression‐free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RM...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Haematol
Main Authors: Dimopoulos, Meletios A., Stewart, A. Keith, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David, Mihaylov, Georgi G., Goranova‐Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej, San‐Miguel, Jesus, Ludwig, Heinz, Palumbo, Antonio, Obreja, Mihaela, Aggarwal, Sanjay, Moreau, Philippe
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2017
Fag:
Haematological Malignancy
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412871/
https://ncbi.nlm.nih.gov/pubmed/28211560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14549
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker